Purpose
Optic pathway gliomas (OPG) are low‐grade pilocytic astrocytomas accounting for 3‐5% of pediatric intracranial tumors. Accurate and quantitative follow‐up of OPG using magnetic resonance imaging (MRI) is crucial for therapeutic decision making, yet is challenging due to the complex shape and heterogeneous tissue pattern which characterizes these tumors. The aim of this study was to implement automatic methods for segmentation and classification of OPG and its components, based on MRI.
Methods
A total of 202 MRI scans from 29 patients with chiasmatic OPG scanned longitudinally were retrospectively collected and included in this study. Data included T2 and post‐contrast T1 weighted images. The entire tumor volume and its components were manually annotated by a senior neuro‐radiologist, and inter‐ and intra‐rater variability of the entire tumor volume was assessed in a subset of scans. Automatic tumor segmentation was performed using deep‐learning method with U‐Net+ResNet architecture. A fivefold cross‐validation scheme was used to evaluate the automatic results relative to manual segmentation. Voxel‐based classification of the tumor into enhanced, non‐enhanced, and cystic components was performed using fuzzy c‐means clustering.
Results
The results of the automatic tumor segmentation were: mean dice score = 0.736 ± 0.025, precision = 0.918 ± 0.014, and recall = 0.635 ± 0.039 for the validation data, and dice score = 0.761 ± 0.011, precision = 0.794 ± 0.028, and recall = 0.742 ± 0.012 for the test data. The accuracy of the voxel‐based classification of tumor components was 0.94, with precision = 0.89, 0.97, and 0.85, and recall = 1.00, 0.79, and 0.94 for the non‐enhanced, enhanced, and cystic components, respectively.
Conclusion
This study presents methods for automatic segmentation of chiasmatic OPG tumors and classification into the different components of the tumor, based on conventional MRI. Automatic quantitative longitudinal assessment of these tumors may improve radiological monitoring, facilitate early detection of disease progression and optimize therapy management.